Join to access to all OVN content. Join for Free

Results for 'personal growth'

...
Partner Avatar Tom Caravela
MSL People Skills: Top 10 Tips for Better Engagement

Apr 20th • 8 mins read

...
Partner Avatar Tom Caravela
Promotability: How to Land Your Next Promotion

May 5th • 10 mins read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 21st • 10 mins read

...
Partner Avatar iNIZIO
Clinical Educator Oncology Program Improves Adherence by 29%​

Sep 3rd • 1 min read

...
Partner Avatar iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care

May 16th • 5 mins read

...
OVN Avatar Karen Geary
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Sep 27th • 1 min read

...
OVN Avatar Ali Raza Khaki
Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Dec 1st • 4 mins read

...
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes
Leveraging existing data to contextualize phase II clinical trial findings in oncology

Sep 21st • 3 mins read

...
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Jun 26th • 18 mins read

...
OVN Avatar Tanja Cufer, Tudor E. Ciuleanu, Peter Berzinec, Gabriela Galffy, Marko Jakopovic, Jacek Jassem, Dragana Jovanovic, Zhasmina Mihaylova, Gyula Ostoros, Christiane Thallinger, Milada Zemanova, Christoph Zielinski
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

Nov 24th • 10 mins read

...
Partner Avatar Envision Pharma Group
Medical affairs: The power behind redefining commercialization

Aug 2nd • 3 mins read

...
OVN Avatar Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD
Evaluating External Validity of Oncology Biosimilar Safety Studies

Apr 6th • 2 mins read

...
OVN Avatar Patrick C. DeMartino, MD, Miloš D. Miljković, MD, MS, Vinay Prasad, MD
Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018

Aug 31st • 7 mins read

...
OVN Avatar Sean P Martin, Xin Wei Wang
The evolving landscape of precision medicine in primary liver cancer

Mar 29th • 3 mins read

...
OVN Avatar Steven Sorscher
Clinical Trials in Oncology and Defining Benefit

Jan 22nd • 1 min read